

Anti-MSLN ADC Against Cancer





Antibody-drug conjugates (ADCs) contain an antibody linked with high potent cytotoxic drugs. ADCs can **target to the tumor cells through the antibody part by recognizing and binding to corresponding tumor antigens**. After internalization, the ADCs are cleaved or digested in the lysosome or endosome and cytotoxic drugs are released to kill the cancer cells. Mesothelin (MSLN) is overexpressed in various cancers like pleural

and peritoneal mesothelioma, ovarian cancer and pancreatic cancer. DCB's patent protected anti-MSLN ADC candidate drug shows **great tumor inhibition**, and belongs to first-in-class drug development.

Indication

- Ovarian cancer
- Pancreatic cancer

Highlights


 <p>Great tumor growth inhibition (>90%) in KLM-1 and OVCAR-3 animal model</p>	 <p>Great efficacy in large tumor model (>500 mm³)</p>	 <p>Proprietary tri-mannosyl conjugation technology applied</p>	 <p>Uniform DAR (4), high affinity, good cytotoxicity</p>
--	---	--	--

Mesothelin: target for cancer treatment


- Mesothelin is a differentiation antigen overexpressed in many solid tumors.
- Its operational tumor selectivity has been clinically proven.
- Anti-MSLN ADC is a potential format against MSLN positive tumors.

Tumor type	No. of patients with MSLN+	Percentage
Mesothelioma (Epithelioid)	248 of 261	95%
Pancreatic adenocarcinoma	303 of 357	85%
Epithelial ovarian cancer	346 of 494	70%
NSCLC (adenocarcinoma)	1082 of 1686	64%
Gastric cancer	312 of 666	47%
Biliary cancer (extrahepatic)	93 of 98	95%
Endometrial cancer	34 of 58	59%
Triple-negative breast cancer	33 of 50	66%

NanoSPECT/CT imaging of anti-MSLN ADC in KLM-1 model



Anti-MSLN ADC showed great potency in ovarian cancer model



Anti-MSLN ADC showed great potency in pancreatic cancer model

